Print

RV 306

Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX? B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults

Trial Details:

II Completed
U.S. Military HIV Research Program (MHRP), National Institute of Allergy and Infectious Diseases (NIAID) September 24, 2013
ALVAC-HIV vCP1521,AIDSVAX B/E Canarypox Env B,E; Protein Env B,E
ALVAC-HIV vCP1521 Viral Vector - Pox
AIDSVAX B/E Protein
Thailand 360
NCT01931358
http://www.clinicaltrials.gov/ct2/show/NCT01931358?term=rv306&rank=1